Alexion Pharmaceuticals Inc (ALXN.O)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|57||2015||Chairman of the Board|
|63||2016||Interim Chief Executive Officer, Director|
|67||2016||Chief Financial Officer|
|56||2014||Chief Human Resource Officer, Executive Vice President|
|48||2014||Executive Vice President, General Counsel|
- BRIEF-Alexion interim CEO says company is not up for sale - conf
- BRIEF-Alexion submits U.S. and EU applications seeking approval of Soliris as a treatment for patients with refractory generalized myasthenia gravis
- BRIEF-FDA grants orphan drug designation to ALXN1210
- Alexion says no need to revise earnings, shares rise
- Alexion Pharmaceuticals says CEO, CFO resign, shares slump